The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency ..read more

ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments ..read more

The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia ..read more

Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ..read more

In May 2024, the ADI delegation returned to Geneva, Switzerland, for the World Health Organization’s 77th annual World Health Assembly to launch ’From Plan To Impact VII: Dementia at a crossroads’. Read ADI's highlights from the event ..read more

ADI is sharing a round-up of our recent action in Europe, on advocacy and research, with ADI Board Vice Chair, Meera Pattabiraman, and ADI Director of Research and Publications, Wendy Weidner. Both taking part in vital dialogues in June 2024.  ..read more

In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond ..read more

Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country ..read more

ADI CEO, Paola Barbarino took to the stage at the ADI 2024 Conference in Krákow, Poland, to highlight the global and national policy landscape on dementia, providing her perspective on the achievements of ADI in the past four decades and hopes for the future ..read more

This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades ..read more